Avi Ashkenazi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Avi Ashkenazi has a total of 411 co-authors. Here are the top co-authors by number of shared publications:
- Scot A. Marsters
Department of Research Oncology, Genentech, Inc., South San Francisco, California
50 shared publications - Joachim Rudolph
Department of Discovery Chemistry, Genentech, Inc., South San Francisco, USA
49 shared publications - Thomas D. Wu
Genentech, South San Francisco, USA
49 shared publications - Jonathan M. Harnoss
University Hospital Heidelberg
48 shared publications - Ioanna Oikonomidi
Department of Research Oncology, Genentech, Inc., South San Francisco, California
47 shared publications - Eileen Tan-Aristy
Department of Research Oncology, Genentech, Inc., South San Francisco, California
46 shared publications
Latest Publications
- Open Access
Peroxisome quality control is gated by a dynamic ATF6α–ABCD3 tether
The endoplasmic reticulum (ER) coordinates protein folding and lipid biosynthesis, while peroxisomes govern fatty-acid catabolism and redox balance. However, little is known about the mechanisms by which these organelles communicate. Here we show that activating transcription factor 6 (ATF6α), a cytoprotective ER-resident sensor of the unfolded protein response (UPR) 1–4 , forms a molecular tether that zippers the ER and peroxisomes together at a 23-nm intermembrane distance. ATF6α achieves this by inserting a short segment of its unstructured N-terminal cytosolic tail into the solvated transmembrane cavity of the peroxisomal ABC-type lipid transporter ABCD3, trapping it in an off-state. This interaction is reinforced by Ceapin, a previously identified small molecule molecular-glue ligand, which promotes ER–peroxisome contact formation 5–7 . The junctions serve as a scaffold that can initiate peroxisome turnover by p62-triggered autophagy (pexophagy), as enhanced lipid processing resulting from organelle zippering leads to peroxisome damage due to excessive reactive oxygen species (ROS) accumulation. These findings define ATF6α as a non-transcriptional regulator of organelle quality control and provide a template for engineering Ceapin analogues against ATF6α/ABCD3-dependent colorectal and hepatocellular cancers and related diseases.
Open AccessPeroxisome quality control is gated by a dynamic ATF6α–ABCD3 tether
The endoplasmic reticulum (ER) coordinates protein folding and lipid biosynthesis, while peroxisomes govern fatty-acid catabolism and redox balance. However, little is known about the mechanisms by which these organelles communicate. Here we show that activating transcription factor 6 (ATF6α), a cytoprotective ER-resident sensor of the unfolded protein response (UPR) 1–4 , forms a molecular tether that zippers the ER and peroxisomes together at a 23-nm intermembrane distance. ATF6α achieves this by inserting a short segment of its unstructured N-terminal cytosolic tail into the solvated transmembrane cavity of the peroxisomal ABC-type lipid transporter ABCD3, trapping it in an off-state. This interaction is reinforced by Ceapin, a previously identified small molecule molecular-glue ligand, which promotes ER–peroxisome contact formation 5–7 . The junctions serve as a scaffold that can initiate peroxisome turnover by p62-triggered autophagy (pexophagy), as enhanced lipid processing resulting from organelle zippering leads to peroxisome damage due to excessive reactive oxygen species (ROS) accumulation. These findings define ATF6α as a non-transcriptional regulator of organelle quality control and provide a template for engineering Ceapin analogues against ATF6α/ABCD3-dependent colorectal and hepatocellular cancers and related diseases.
- Open Access
- 9 July 2026
- Published by Springer Nature in Cell Death & Differentiation
- p. 1-17
Epithelial cancer cells co-opt the death ligand TRAIL to avert extrinsic apoptosis while acquiring killing capacity
Cancer cells avert apoptosis to sustain growth, evade immunity, and resist therapy. However, how they escape specific extrinsic death signals remains unclear. We show that certain epithelial carcinomas co-opt the death-receptor ligand Apo2L/TRAIL to suppress apoptosis while acquiring killing capacity. Analysis of CRISPR knockout screens from the Cancer Dependency Map uniquely identified TRAIL as an essential tumor necrosis factor superfamily member in epithelial malignancies. Renal cell carcinomas (RCC) and squamous cell carcinomas (SCC) expressed TRAIL within both malignant and nonmalignant compartments. In RCC, loss of the tumor suppressor VHL induced HIF2α-dependent TRAIL transcription, whereas in SCC, 3q26 amplification increased TRAIL abundance. Fractional TRAIL silencing revealed killing of TRAIL-deficient cells by TRAIL-expressing counterparts, while full silencing sensitized cells to extrinsic TRAIL. Mechanistically, endogenous TRAIL suppressed apoptosis through lysosomal degradation of its cognate death receptors. Thus, cancer cells can repurpose TRAIL via a surprising apoptotic “cloak-and-dagger” mechanism with significant therapeutic potential.
- 9 July 2026
- Published by Springer Nature in Cell Death & Differentiation
- p. 1-17
Open AccessEpithelial cancer cells co-opt the death ligand TRAIL to avert extrinsic apoptosis while acquiring killing capacity
Cancer cells avert apoptosis to sustain growth, evade immunity, and resist therapy. However, how they escape specific extrinsic death signals remains unclear. We show that certain epithelial carcinomas co-opt the death-receptor ligand Apo2L/TRAIL to suppress apoptosis while acquiring killing capacity. Analysis of CRISPR knockout screens from the Cancer Dependency Map uniquely identified TRAIL as an essential tumor necrosis factor superfamily member in epithelial malignancies. Renal cell carcinomas (RCC) and squamous cell carcinomas (SCC) expressed TRAIL within both malignant and nonmalignant compartments. In RCC, loss of the tumor suppressor VHL induced HIF2α-dependent TRAIL transcription, whereas in SCC, 3q26 amplification increased TRAIL abundance. Fractional TRAIL silencing revealed killing of TRAIL-deficient cells by TRAIL-expressing counterparts, while full silencing sensitized cells to extrinsic TRAIL. Mechanistically, endogenous TRAIL suppressed apoptosis through lysosomal degradation of its cognate death receptors. Thus, cancer cells can repurpose TRAIL via a surprising apoptotic “cloak-and-dagger” mechanism with significant therapeutic potential.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Wnt surrogate restores Wnt-pathway activity and growth of PDM-272 organoids in context of ATF6 inhibition
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Wnt surrogate restores Wnt-pathway activity and growth of PDM-272 organoids in context of ATF6 inhibition
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Annotation of CRC organoid mutations
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Annotation of CRC organoid mutations
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Comparison of ER13 and ER16 gene signatures
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Comparison of ER13 and ER16 gene signatures
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
ATF6 disruption decreases CRC cell seeding capacity
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
ATF6 disruption decreases CRC cell seeding capacity
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
β-catenin knockdown phenocopies ATF6 silencing
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
β-catenin knockdown phenocopies ATF6 silencing
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
ATF6 disruption attenuates cell cycle progression and upregulates specific CDK inhibitors
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
ATF6 disruption attenuates cell cycle progression and upregulates specific CDK inhibitors
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
CRC tumors display elevated expression of ATF6 target genes
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
CRC tumors display elevated expression of ATF6 target genes